Akero Therapeutics (NASDAQ:AKRO) Shares Down 3.3% - Time to Sell?

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report)'s stock price dropped 3.3% on Monday . The company traded as low as $53.14 and last traded at $53.81. Approximately 104,600 shares traded hands during trading, a decline of 90% from the average daily volume of 1,005,927 shares. The stock had previously closed at $55.62.

Wall Street Analyst Weigh In

AKRO has been the subject of a number of research reports. HC Wainwright raised their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Citigroup reduced their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, Bank of America raised their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $82.50.

Akero Therapeutics Stock Down 0.9%

The business's 50 day moving average is $45.51 and its 200 day moving average is $40.94. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80. The stock has a market cap of $4.38 billion, a price-to-earnings ratio of -28.15 and a beta of -0.16.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. Equities analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Insider Buying and Selling

In other Akero Therapeutics news, VP Patrick Lamy sold 8,000 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $42.49, for a total value of $339,920.00. Following the completion of the sale, the vice president now owns 33,492 shares in the company, valued at $1,423,075.08. This represents a 19.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Timothy Rolph sold 25,000 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $55.04, for a total transaction of $1,376,000.00. Following the completion of the sale, the insider now owns 169,721 shares of the company's stock, valued at approximately $9,341,443.84. The trade was a 12.84% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 206,787 shares of company stock valued at $9,507,000. Company insiders own 7.07% of the company's stock.

Institutional Investors Weigh In On Akero Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. lifted its position in Akero Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company's stock worth $72,000 after buying an additional 321 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Akero Therapeutics by 14.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company's stock worth $114,000 after buying an additional 338 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Akero Therapeutics by 30.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock worth $67,000 after buying an additional 390 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Akero Therapeutics by 19.0% during the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company's stock valued at $104,000 after purchasing an additional 410 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its holdings in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock valued at $197,000 after purchasing an additional 450 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.